Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1)

The summary for the Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1): -Purpose. The goal of this funding opportunity announcement (FOA) is to accelerate the development of safe and effective medical products to mitigate and treat thrombocytopenia and to enhance platelet regeneration after radiation exposure from radiological and nuclear terrorist attacks. Specifically, this new initiative will support research and development of promising new approaches and medical products to enhance platelet regeneration and yield improved survival. -Among the most important medical countermeasures against acute radiation syndrome are those that will treat or mitigate its hematopoietic component. Certain radiation exposures can cause severe damage to the bone marrow, which can have dramatic effects on circulating blood cells, including platelets, neutrophils, lymphocytes, and erythrocytes,. Platelets play an essential role in hemostasis and thrombosis. As the level of circulating platelets drops below 20,000/mm3 (a condition referred to as severe thrombocytopenia ), the risk to an affected individual for catastrophic hemorrhage increases markedly. Severe thrombocytopenia is clearly a contributor to mortality following radiation exposure. Currently, there is no approved therapeutic drug in the Strategic National Stockpile for this radiation-induced complication. -Mechanism of Support. This FOA will utilize the NIH Challenge Grant (RC1) award mechanism.
Federal Grant Title: Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-AI-07-036
Type of Funding: Grant
CFDA Numbers: 93.855
CFDA Descriptions: Allergy, Immunology and Transplantation Research
Current Application Deadline: No deadline provided
Original Application Deadline: Jan 10, 2008
Posted Date: Sep 27, 2007
Creation Date: Nov 09, 2007
Archive Date: Feb 09, 2008
Total Program Funding: $4,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses State governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K0...
Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinica...
Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinica...
Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals...
NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)
Center for HIV/AIDS Vaccine Immunology (CHAVI)
Genomics of Transplantation Cooperative Research Program
Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health
Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K0...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinica...
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com